0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Delirium Drug"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
Delirium - Pipeline Insight, 2025 - Product Thumbnail Image

Delirium - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
EUR$2,000USDGBP
Delirium - Global Clinical Trials Review, 2024 - Product Thumbnail Image

Delirium - Global Clinical Trials Review, 2024

  • Clinical Trials
  • August 2024
  • 529 Pages
  • Global
From
EUR$3,450USDGBP
From
EUR$6,499USDGBP
From
EUR$7,950USDGBP
  • 4 Results (Page 1 of 1)
Loading Indicator

Delirium is a type of mental disorder characterized by confusion, disorientation, and disturbances in attention, thought, and behavior. It is a common complication of critical illness and is associated with increased mortality and morbidity. Delirium is a major public health problem, particularly in elderly patients. The delirium drug market is a subset of the larger Central Nervous System (CNS) drug market. CNS drugs are used to treat a variety of neurological and psychiatric disorders, including delirium. The delirium drug market is expected to grow due to the increasing prevalence of delirium in elderly patients, as well as the development of new drugs to treat the condition. Some of the major companies in the delirium drug market include Pfizer, Merck, Johnson & Johnson, Novartis, and Eli Lilly. These companies are involved in the development and marketing of drugs for the treatment of delirium. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more